ID   DU145/RC0.1
AC   CVCL_AS75
SY   DU145 RC0.1; RC0.1; RCO.1; RC01
DR   cancercelllines; CVCL_AS75
DR   GEO; GSM750772
DR   GEO; GSM799380
DR   GEO; GSM799443
DR   GEO; GSM1153443
DR   GEO; GSM1181318
DR   GEO; GSM1181329
DR   Progenetix; CVCL_AS75
DR   Wikidata; Q54831575
RX   PubMed=11280753;
RX   PubMed=12615715;
RX   PubMed=19372543;
RX   PubMed=22347499;
RX   PubMed=24670534;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90225; Rubitecan (Orathecin; 9-nitrocamptothecin; 9NC).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg364His (c.1091G>A); Zygosity=Homozygous (PubMed=11280753).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=19372543
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12,14
ST   D18S51: 12
ST   D19S433: 13
ST   D21S11: 30,33
ST   D2S1338: 16,17
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 7,11
ST   D8S1179: 13,14
ST   FGA: 22
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0105 ! DU145
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 05-10-23; Version: 16
//
RX   PubMed=11280753;
RA   Urasaki Y., Laco G.S., Pourquier P., Takebayashi Y., Kohlhagen G.,
RA   Gioffre C., Zhang H.-L., Chatterjee D., Pantazis P., Pommier Y.;
RT   "Characterization of a novel topoisomerase I mutation from a
RT   camptothecin-resistant human prostate cancer cell line.";
RL   Cancer Res. 61:1964-1969(2001).
//
RX   PubMed=12615715;
RA   Reinhold W.C., Kouros-Mehr H., Kohn K.W., Maunakea A.K., Lababidi S.,
RA   Roschke A.V., Stover K., Alexander J., Pantazis P., Miller L., Liu E.T.,
RA   Kirsch I.R., Urasaki Y., Pommier Y., Weinstein J.N.;
RT   "Apoptotic susceptibility of cancer cells selected for camptothecin
RT   resistance: gene expression profiling, functional analysis, and
RT   molecular interaction mapping.";
RL   Cancer Res. 63:1000-1011(2003).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//